Extracellular Vesicles (EVs) as Biomakers

Cancer cells secrete DNA, large cancer cells [CTCs], and Extracellular Vesicles [EVs] into the blood.

CellSpring's tests target EVs because they are present in much higher amounts and they show up in the blood earlier than either CTCs or cfDNA.  This allows for detection of the earliest possible traces of a tumor in a patient's blood.

Untitled design - 2021-06-30T095737.156.png
Untitled design - 2021-06-30T100710.415.png

EV Molecular Cargoes

All cells secrete EVs that are packed with molecular information from their cells of origin.  The challenge to using EVs as diagnostic biomarkers is to pinpoint the exact molecular signature of EVs that come from cancer cells. 


CellSpring’s 3D Bloom technology accomplishes this by tricking cancer cells into producing large quantities of EVs packed with cancer-specific molecular cargo.

Our Platform Workflow


3D Bloom tricks cancer cells into revealing the molecular information they pack into EVs.


CellSpring’s proprietary algorithm identifies cancer-specific cargo in EVs from cancer cells

Biomarkers on EV surfaces 

identified using 3D Bloom

Untitled design - 2021-06-30T102742.970.png
Untitled design - 2021-06-30T102604.958.png

EV Diagnostics

CellSpring then develops minimally invasive diagnostic tests designed to isolate cancer EVs that might be present in a patient’s blood sample.  The concentration of cancer EVs in a patient’s blood can be critical for catching cancer in its earliest stages, and provide an oncologist critical information for follow-up and eventual therapeutic intervention.

Untitled design - 2021-06-30T103920.156.png